Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. - Wikidata - wikimedia - TriplyDB

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.

http://www.wikidata.org/entity/Q42017054

about

The steady progress of targeted therapies, promising advances for lung cancer Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer Preclinical Murine Models for Lung Cancer: Clinical Trial Applications Epidermal growth factor signaling in transformed cells Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.Guidelines for the welfare and use of animals in cancer research.Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma How genetically engineered mouse tumor models provide insights into human cancers Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.Mouse models for lung cancer Metastasized lung cancer suppression by Morinda citrifolia (Noni) leaf compared to Erlotinib via anti-inflammatory, endogenous antioxidant responses and apoptotic gene activation.EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.Morinda citrifolia edible leaf extract enhanced immune response against lung cancer.Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.Commentary on tumor heterogeneity.Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.

P2860

Q26746895-28339087-AD73-4AD4-8272-5F8D9C12D8AA Q26798147-8B46200D-A40D-4677-A2BC-2D2ECD2B478C Q26863474-B2A3AC34-309F-403E-8C0A-1F97D68EF9B0 Q28084034-4CC1B419-E1ED-4C9B-B2AD-1FD70CBE54AD Q28115136-197F5C27-E3A7-410E-97C0-9874485334CA Q28259999-0B51CE1B-126B-47C1-ABD7-20BD18B70535 Q33572728-80DD90D2-94BE-42D9-AF72-8497D04AA7C9 Q33819404-0B5D74A5-CB81-411D-9588-B23DFFDE69F1 Q33903753-845EDEFB-A814-4A1B-B03B-D1599100E46B Q34676770-D4867CC6-F25C-45A0-A1AC-2A5C8B76DE05 Q34773458-B165A7AA-6694-44EB-ACBD-03C2C71A95E0 Q35816386-8DF2F652-F18A-4392-B667-3C88FE88FFA7 Q36140332-2F3EBB15-E82A-4768-8C60-E0FC04159BAF Q36322762-3169A56D-8876-4412-B68A-537482BB0142 Q36471537-27012830-17B4-4053-B3B5-9A8D323816D8 Q37065678-2FC193BC-89BB-445A-90F8-1A91280A7AF1 Q37369422-EFF59103-225C-4E30-A89D-ED68A3FD50A9 Q37628915-D4FA8D11-BFA2-4DE0-9C5F-DC3475A443FE Q38025261-BA921EAD-4189-41D4-A2D2-30CD90C35B55 Q38088500-C09F4E75-C2B9-4CB7-940C-7A255089CBBE Q38776120-CDDB99E8-935E-48E0-8A34-EC39EC4E5167 Q39430432-A66AB0A5-1C3D-4CC8-809F-895879B9A8F9 Q40977881-17ADFBF5-63C9-476A-B558-48ED69221C50 Q42043613-8BB1FB72-E129-4F06-9907-4B82841F73FC Q42398711-DF23D881-BFEE-4B3B-A05B-EB67639B33DB Q45983599-DDCC7F82-4FCD-4618-9913-046409D378F8 Q47119773-D248F5FC-5DBE-457C-9A77-3F477B0ED991 Q47146662-9C9732CF-2886-4139-A107-2463ECA05771

P2860

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.

http://www.wikidata.org/entity/Q42017054

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Erlotinib resistance in mouse ...... r-induced lung adenocarcinoma.

@en

Erlotinib resistance in mouse ...... r-induced lung adenocarcinoma.

@nl

type

label

Erlotinib resistance in mouse ...... r-induced lung adenocarcinoma.

@en

Erlotinib resistance in mouse ...... r-induced lung adenocarcinoma.

@nl

prefLabel

Erlotinib resistance in mouse ...... r-induced lung adenocarcinoma.

@en

Erlotinib resistance in mouse ...... r-induced lung adenocarcinoma.

@nl

P1433

Q42017054-35133CC4-6B04-433F-93D3-45744B1FAF41

P1476

Q42017054-76325866-E434-49E0-A8B0-3B5364E0BB7D

P2093

Q42017054-3FD6A8C7-7770-4654-AE2F-19713C9A1DFB

Q42017054-8D96E050-82D9-4263-94C9-2FFB983EF2DB

Q42017054-BFC3C194-5374-4C74-917A-68589A81149A

P2860

Q42017054-03A11CD7-C9C8-403F-8FCC-AE9E52D7AEBC

Q42017054-1CE7D594-9610-43D9-815D-979C100E50F5

Q42017054-21A7C718-AA5D-4A58-A673-ADE9E2D37ECA

Q42017054-27259A18-F50D-4642-8709-FA07E7657BAC

Q42017054-2EEC8F1D-8E05-48F2-A8D7-154A210CCA14

Q42017054-30BF53F6-5794-4EC5-A2CB-AB8D7D0192AB

Q42017054-38B2F61A-CCCD-4A1B-9FBC-965936FEC79A

Q42017054-489A06E4-D961-4F81-87FA-E3558CA492D4

Q42017054-49D7AF42-1435-4762-87FF-6DE8327E510F

Q42017054-4B77B5A8-25C1-4EE1-91B3-DCCFC3840CE9

P304

Q42017054-F382D565-C055-43E4-AF81-51CBAD70F97B

P31

Q42017054-6B7397C3-4D93-4485-BE01-CD72D9894926

P356

Q42017054-CC6100A6-7121-40D8-A272-90BB33F521A5

P433

Q42017054-67DD8B47-34C9-4305-A8E5-C352B8D6795E

P478

Q42017054-47B92B49-27EC-4926-8CF8-833655DC98D4

P50

Q42017054-4B497D20-D8E1-4FE5-B7AF-34FD35E80006

Q42017054-B639A60D-B50E-4642-9D3A-67E1E4AC4356

P577

Q42017054-F47FAAE0-4E4F-49F0-886E-8C3A97DF7AD8

P5875

Q42017054-70E7B408-7362-4952-807C-73F7562DB175

P698

Q42017054-BD015575-AF49-4F7F-A814-2D016D71CCC3

P921

Q42017054-A90EED29-7637-4E2D-B4A5-F35A0C7C994A

P932

Q42017054-D3243845-A194-42A2-A877-D02AEB71E419

P356

P1433

Disease Models & Mechanisms

P1476

Erlotinib resistance in mouse ...... r-induced lung adenocarcinoma.

@en

P2093

Maureen Zakowski

http://www.w3.org/2001/XMLSchema#string

Pang-Dian Fan

http://www.w3.org/2001/XMLSchema#string

Ronglai Shen

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

111-119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1242/DMM.003681

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Harold E. Varmus

Katerina Politi

P577

2009-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40685245

http://www.w3.org/2001/XMLSchema#string

P698

20007486

http://www.w3.org/2001/XMLSchema#string

P921

P932

2806903

http://www.w3.org/2001/XMLSchema#string